Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Primer for advisory panels

This article was originally published in The Tan Sheet

Executive Summary

CHPA's Scientific Affairs Committee is looking into ways to help improve the advisory committee review process. The SAC is working on "a document that sort of takes...frequently asked questions, and lays out some of the basics as a primer for advisory committee members," according to Committee Chair Ed Hemwall (J&J/Merck Consumer Pharmaceuticals). SAC would seek FDA endorsement of the document and would then provide it to advisory panel members prior to meetings. The document has not yet been drafted, but its purpose would be to "make sure that committee members understand going into the room the fundamentals of OTC study," such as consumer behavior trials and advertising regulation, Hemwall said. The information would "perhaps help reduce some of the off-topic debate and uninformed speculation that often occurs at these meetings," he added...

You may also be interested in...



From Availability To Awareness: 2007 Brings Wide Range Of Goals For CHPA

The Consumer Healthcare Products Association looks to focus its efforts in 2007 on issues such as Rx-to-OTC switches, rising health care costs, consumer education and prevention of OTC abuse. CHPA President Linda Suydam recently spoke with "The Tan Sheet" about the association's accomplishments during 2006 and goals for the coming year

UK Regulator Puts Energies Into COVID-19 While Other Services May Take Longer

With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Topics

UsernamePublicRestriction

Register

PS099353

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel